355
Views
1
CrossRef citations to date
0
Altmetric
Original Articles: NACP Symposium on Radiophysics

A national repository of complete radiotherapy plans: design, Results, and experiences

, ORCID Icon, ORCID Icon, , , , , ORCID Icon, ORCID Icon, ORCID Icon, , , ORCID Icon, , , , ORCID Icon & ORCID Icon show all
Pages 1161-1168 | Received 19 Apr 2023, Accepted 04 Oct 2023, Published online: 18 Oct 2023

References

  • Brink C, Lorenzen EL, Krogh SL, et al. DBCG hypo trial validation of radiotherapy parameters from a national data bank versus manual reporting. Acta Oncol. 2018;57(1):107–112. doi: 10.1080/0284186X.2017.1406140.
  • RadioTherapy DCCC. DCCC Radiotherapy Webpage. 2018. Available from: https://www.straaleterapi.dk/en
  • (MITA) MITA. Digital imaging and communication in medicine. 2023. Available from: https://www.dicomstandard.org/
  • Wilkinson MD, Dumontier M, Aalbersberg IJ, et al. The FAIR guiding principles for scientific data management and stewardship. Sci Data. 2016;3(1):160018. doi: 10.1038/sdata.2016.18.
  • Moller S, Jensen MB, Ejlertsen B, et al. The clinical database and the treatment guidelines of the danish breast cancer cooperative group (DBCG); its 30-years experience and future promise. Acta Oncol. 2008;47(4):506–524. doi: 10.1080/02841860802059259.
  • Overgaard J, Jovanovic A, Godballe C, et al. The danish head and neck cancer database. Clin Epidemiol. 2016;8:491–496. doi: 10.2147/CLEP.S103591.
  • Westberg J, Krogh SL, Brink C, et al. A DICOM based radiotherapy plan database for research collaboration and reporting. In Journal of Physics: Conference Series. 2014, 489. doi: 10.1088/1742-6596/489/1/012100.
  • Van Herk M. Conquest DICOM software. 2023. Available from: https://ingenium.home.xs4all.nl/dicom.html
  • Amt F. Omsorgssektoren på sundhedsdatanettet (the care sector on health data net). Odense: fyns Amt/MedCom (internetudgave); 2000.
  • Yeh J. ClearCanvas GitHub Github; 2015.
  • Zukauskaite R, Brink C, Hansen CR, et al. Open source deformable image registration system for treatment planning and recurrence CT scans: validation in the head and neck region. Strahlenther Onkol. 2016;192(8):545–551. doi: 10.1007/s00066-016-0998-4.
  • Zukauskaite R, Hansen CR, Brink C, et al. Analysis of CT-verified loco-regional recurrences after definitive IMRT for HNSCC using site of origin estimation methods. Acta Oncol. 2017;56(11):1554–1561. doi: 10.1080/0284186X.2017.1346384.
  • Zukauskaite R, Hansen CR, Grau C, et al. Local recurrences after curative IMRT for HNSCC: effect of different GTV to high-dose CTV margins. Radiother Oncol. 2018;126(1):48–55. doi: 10.1016/j.radonc.2017.11.024.
  • Offersen BV. Hypofractionated loco-regional adjuvant radiation therapy of breast cancer combined with a simultaneous integrated boost. 2015. Available from: https://clinicaltrials.gov/show/NCT02384733
  • Offersen BV, Alsner J, Nielsen HM, et al. Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III trial: the DBCG HYPO trial. J Clin Oncol. 2020;38(31):3615–3625. doi: 10.1200/JCO.20.01363.
  • Offersen BV, Alsner J, Nielsen HM, et al. Partial breast irradiation versus whole breast irradiation for early breast cancer patients in a randomized phase III trial: the danish breast cancer group partial breast irradiation trial. J Clin Oncol. 2022;40(36):4189–4197. doi: 10.1200/JCO.22.00451.
  • Friborg J. DAHANCA 35: proton versus photon therapy for head-neck cancer. 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04607694
  • Hansen O, Knap MM, Khalil A, et al. A randomized phase II trial of concurrent chemoradiation with two doses of radiotherapy, 60 Gy and 66 Gy, concomitant with a fixed dose of oral vinorelbine in locally advanced NSCLC. Radiother Oncol. 2017;123(2):276–281. doi: 10.1016/j.radonc.2017.03.017.
  • Moller DS, Nielsen TB, Brink C, et al. Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): design and early dosimetric results of a randomized, multi-Centre phase-III study. Radiother Oncol. 2017;124(2):311–317. doi: 10.1016/j.radonc.2017.06.022.
  • Finnegan R, Lorenzen EL, Dowling J, et al. Analysis of cardiac substructure dose in a large, multi-Centre danish breast cancer cohort (the DBCG HYPO trial): trends and predictive modelling. Radiother Oncol. 2020;153:130–138. doi: 10.1016/j.radonc.2020.09.004.
  • Thomsen MS, Alsner J, Nielsen HM, et al. Volume matters: breast induration is associated with irradiated breast volume in the danish breast cancer group phase III randomized partial breast irradiation trial. Radiother Oncol. 2022;177:231–235. doi: 10.1016/j.radonc.2022.09.024.
  • Berg M, Lorenzen EL, Jensen I, et al. The potential benefits from respiratory gating for breast cancer patients regarding target coverage and dose to organs at risk when applying strict dose limits to the heart: results from the DBCG HYPO trial. Acta Oncol. 2018;57(1):113–119. doi: 10.1080/0284186X.2017.1406139.
  • von Buchwald C. Quality of life after primary TORS vs IMRT for patients with early-stage oropharyngeal squamous cell carcinoma (QoLATI). 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT04124198
  • Offersen BV. The DBCG proton trial: photon versus proton radiation therapy for early breast cancer. 2020. Available from: https://clinicaltrials.gov/show/NCT04291378
  • Milo MLH, Offersen BV, Bechmann T, et al. Delineation of whole heart and substructures in thoracic radiation therapy: national guidelines and contouring atlas by the danish multidisciplinary cancer groups. Radiother Oncol. 2020;150:121–127. doi: 10.1016/j.radonc.2020.06.015.
  • Lorenzen EL, Kallehauge JF, Byskov CS, et al. A national study on the inter-observer variability in the delineation of organs at risk in the brain. Acta Oncol. 2021;60(11):1548–1554. doi: 10.1080/0284186X.2021.1975813.
  • Hoffmann L, Knap MM, Khalil AA, et al. The NARLAL2 dose escalation trial: dosimetric implications of inter-fractional changes in organs at risk. Acta Oncol. 2018;57(4):473–479. doi: 10.1080/0284186X.2017.1366049.
  • Seibold P, Webb A, Aguado-Barrera ME, et al. REQUITE: a prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. Radiother Oncol. 2019;138:59–67. doi: 10.1016/j.radonc.2019.04.034.
  • de Mol van Otterloo SR, Christodouleas JP, Blezer ELA, et al. The MOMENTUM study: an international registry for the Evidence-Based introduction of MR-Guided adaptive therapy. Front Oncol. 2020;10:1328. doi: 10.3389/fonc.2020.01328.
  • Wisconsis-Madison Uo. Wisconsin oncology network of imaging excellence (WONIX). 2023. Available from: https://cancer.wisc.edu/research/innovation/wonix/
  • Ebert MA, Haworth A, Kearvell R, et al. Detailed review and analysis of complex radiotherapy clinical trial planning data: evaluation and initial experience with the SWAN software system. Radiother Oncol. 2008;86(2):200–210. doi: 10.1016/j.radonc.2007.11.013.
  • Wahid KA, Lin D, Sahin O, et al. Large scale crowdsourced radiotherapy segmentations across a variety of cancer anatomic sites. Sci Data. 2023;10(1):161. doi: 10.1038/s41597-023-02062-w.
  • Ab E. ProKnow webpage 2023. Available from: https://proknowsystems.com/
  • Hansen CR, Price G, Field M, et al. Larynx cancer survival model developed through open-source federated learning. Radiother Oncol. 2022;176:179–186. doi: 10.1016/j.radonc.2022.09.023.
  • Hansen CR, Price G, Field M, et al. Open-source distributed learning validation for a larynx cancer survival model following radiotherapy. Radiother Oncol. 2022;173:319–326. doi: 10.1016/j.radonc.2022.06.009.
  • Fonden NN. Data Science Research Infrastructure 2022 2022. Available from: https://novonordiskfonden.dk/en/grant/data-science-research-infrastructure-2022/
  • Eriksen JG, Maare C, Johansen J, et al. Evaluation of the EGFR-Inhibitor zalutumumab given with primary curative (chemo)radiation therapy to patients with squamous cell carcinoma of the head and neck: results of the DAHANCA 19 randomized phase 3 trial. Int J Radiat Oncol Biol Phys. 2014;88(2):465. doi: 10.1016/j.ijrobp.2013.11.021.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.